Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DBV TechnologiesDBVT -1.46%31 Cash-to-Debt is 22.71 as of Jun. 2026, which is 62% above its 10-year median of 14.05. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,401 Biotechnology companies, DBV Technologies ranks better than 64.17% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. DBV Technologies's cash to debt ratio for the quarter that ended in Jun. 2026 was 22.71.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, DBV Technologiescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for DBV Technologies's Cash-to-Debt or its related term are showing as below:
DBVT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.79 Med: 14.05 Max: 67.84
Current: 22.72
During the past 13 years, DBV Technologies's highest Cash to Debt Ratio was 67.84. The lowest was 1.79. And the median was 14.05.
DBVT's Cash-to-Debt is ranked better than 64.17% of 1401
companies
in the Biotechnology industry
Industry Median: 6.56
vs DBVT: 22.72
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
DBV Technologies Cash-to-Debt Related Terms
DBV Technologies Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for DBV Technologies's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, DBV Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (DBVT) has a Cash-to-Debt of 22.71 as of Jun. 2026. This is 62% above median its historical median of 14.05. Over the past decade, DBV Technologies' Cash-to-Debt has ranged from 1.79 to 67.84. According to the industry distribution chart, DBV Technologies ranks #502 out of 1401 companies in the Biotechnology industry, placing it in the top 35.8%.
Is DBV Technologies' Cash-to-Debt too high?
DBV Technologies' current Cash-to-Debt of 22.71 is 62% above median its 10-year median of 14.05. Over the past 10 years, this metric has ranged from a low of 1.79 to a high of 67.84. The Biotechnology industry median Cash-to-Debt is 6.56. DBV Technologies' value of 22.71 is 246.2% above this industry median. Based on the distribution chart, DBV Technologies ranks #502 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #502 out of 1401 companies for Cash-to-Debt. This puts DBV Technologies in the upper half of its industry. The industry median Cash-to-Debt is 6.56. DBV Technologies' value of 22.71 is 246.2% above this benchmark. Historically, DBV Technologies' own Cash-to-Debt has ranged from 1.79 to 67.84 over the past decade. While the company's 10-year median is 14.05 vs. the industry median of 6.56, DBV Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.56, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DBV Technologies's current Cash-to-Debt of 22.71 is 246.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current Cash-to-Debt is 22.71, which is 62% above median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Cash-to-Debt of 22.71. The current Cash-to-Debt is 22.71, which is 62% above median its 10-year median of 14.05 and 246.2% above the Biotechnology industry median of 6.56. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Cash-to-Debt is 22.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score
Get the complete analysis for DBVT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVT has been successfully added to your 
